Amgen-AstraZeneca Psoriatic Arthritis Drug Shows Improvement - Analyst Blog

By
A A A

AstraZeneca ( AZN ) and partner Amgen ( AMGN ) announced that data from a phase II study (n = 168) evaluating the use of brodalumab in patients suffering from psoriatic arthritis was published in The New England Journal of Medicine (NEJM). The data will also be presented at the annual meeting of the European League Against Rheumatism (EULAR).

In the randomized, double-blind, placebo-controlled, phase II study, brodalumab demonstrated significant improvement (measured using the American College of Rheumatology score of 20% improvement/ACR20) in signs and clinical symptoms associated with psoriatic arthritis including tender and swollen joints at 12 weeks. It was also found that several patients continued to improve and the improvement was sustained through the first 52 weeks of the study.

Amgen and AstraZeneca are currently conducting two phase III studies (AMVISION-1 and AMVISION-2) evaluating the use of brodalumab in patients suffering from psoriatic arthritis. The study will also assess brodalumab's ability to prevent joint damage.

Apart from psoriatic arthritis, the companies are evaluating brodalumab for moderate-to-severe plaque psoriasis (phase III) and asthma (phase II).

Both Amgen and AstraZeneca are working on strengthening their product portfolio and brodalumab is one of the key candidates in their pipeline. According to a press release issued by AstraZeneca, analysts estimate peak sales of brodalumab to range between $0.5 billion and $1.5 billion.

Amgen and AstraZeneca are both Zacks Rank #3 (Hold) stocks. Some better-ranked stocks in the health care sector include Gilead Sciences ( GILD ) and Allergan ( AGN ). Both Gilead and Allergan are Zacks Rank #1 (Strong Buy) stocks.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

ALLERGAN INC (AGN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

AMGEN INC (AMGN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AZN , AGN , GILD , AMGN

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Cheap Ways to Sleep Better
Cheap Ways to Sleep Better          

Stocks

Referenced

Most Active by Volume

105,679,298
  • $16.13 ▼ 0.19%
43,130,824
  • $101.32 ▲ 0.74%
24,108,376
  • $59.80 ▲ 7.34%
22,524,427
  • $26.15 ▼ 1.06%
22,194,114
  • $24.65 ▼ 0.96%
21,835,360
  • $99.05 ▲ 0.15%
20,872,575
  • $34.94 ▼ 0.60%
20,561,803
    $74.57 unch
As of 8/22/2014, 04:02 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com